



© Copyright 2012 Oregon State University. All Rights Reserved

Drug Use Research & Management Program
OHA Division of Medical Assistance Programs
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | Fax 503-947-1119



Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, August 6th, 2026 1:00 - 5:00 PM

Remote Meeting via Zoom Platform

MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

I. CALL TO ORDER

- | | | |
|---------|--|---|
| 1:00 PM | <ul style="list-style-type: none"> A. Roll Call & Introductions B. Conflict of Interest Declaration C. Approval of Agenda and Minutes D. Department Update E. Mental Health Clinical Advisory Group | <ul style="list-style-type: none"> R. Citron (OSU) R. Citron (OSU) R. Citron (OSU) T. Douglass (OHA) A. Gibler (OHA) |
|---------|--|---|

- | | | |
|---------|---|--------------------|
| 1:20 PM | <h4>II. CONSENT AGENDA TOPICS</h4> <ul style="list-style-type: none"> A. Quarterly Utilization Reports B. Oncology Prior Authorization Updates C. Literature Scans <ul style="list-style-type: none"> 1. Drugs for Diabetes <ul style="list-style-type: none"> a. GLP-1 Receptor Agonists and GIP Therapies b. Oral Medications for Diabetes 2. Glaucoma Drugs 3. Antianginals 4. Ophthalmic Anti-inflammatory Drugs 5. Topical Steroids 6. Antihypertensive Drugs <ul style="list-style-type: none"> a. Combination Antihypertensive b. Beta-blockers, Oral c. Calcium Channel Blockers 7. Potassium and Potassium Phosphate, Oral Products D. Public Comment | S. Ramirez (Chair) |
|---------|---|--------------------|

1:25 PM III. DUR ACTIVITIES

- | | |
|--|--|
| <ul style="list-style-type: none"> A. ProDUR Report B. RetroDUR Report C. Oregon State Drug Review <ul style="list-style-type: none"> 1. Update on Targeted Immune Modulators Used to Manage Selected Autoimmune Conditions | <ul style="list-style-type: none"> L. Starkweather (Gainwell) D. Engen (OSU) K. Sentena (OSU) |
|--|--|

2. Chronic Kidney Disease Pharmacotherapy:
Guideline Updates & Practical Application
3. Eating Disorders and Disordered Eating Behaviors
in Patients with Diabetes

IV. OLD BUSINESS

- | | |
|-----------------------------------|-----------------|
| A. Healthier Oregon Policy Update | S. Servid (OSU) |
| 1. Antifungals, Oral | |

V. NEW BUSINESS

- | | | |
|---------|---|-------------------|
| 1:45 PM | A. Redempro® (plozasiran) New Drug Evaluation
1. New Drug Evaluation/Prior Authorization Criteria
2. Public Comment
3. Discussion and Clinical Recommendations to OHA | M. Herink (OSU) |
| 2:00 PM | B. Newer Drugs for Heart Failure Literature Scan
1. Literature Scan ARNI and Diuretics
2. Prior Authorization Criteria
3. Public Comment
4. Discussion and Clinical Recommendations to OHA | D. Moretz (OSU) |
| 2:15 PM | C. Tzield® (teplizumab) Prior Authorization Update
1. Prior Authorization Criteria
2. Public Comment
3. Discussion and Clinical Recommendations to OHA | K. Sentena (OSU) |
| 2:20 PM | D. Herpes Simplex Class Update
1. Class Update/Prior Authorization Criteria
2. Public Comment
3. Discussion and Clinical Recommendations to OHA | K. Sentena (OSU) |
| 2:40 PM | E. Enzyme Replacement for Hunter Syndrome Orphan
Drug Evaluations
1. Elaprase® (idursulfase) Orphan Evaluation
2. Avlayah™ (tvidenofusp alfa) Orphan Evaluation
3. Prior Authorization Criteria
4. Public Comment
5. Discussion and Clinical Recommendations to OHA | D. Moretz (OSU) |
| 2:55 PM | BREAK | |
| 3:10 PM | F. Monoclonal Antibodies for Lupus Class Update and
New Drug Evaluation
1. Gazyva® (obinutuzumab) New Drug Evaluation
2. Class Update/Prior Authorization Criteria
3. Public Comment | S. Fletcher (OSU) |

4. Discussion and Clinical Recommendations to OHA

3:25 PM

G. C-Type Natriuretic Peptides Class Update and New Drug Evaluation

D. Moretz (OSU)

1. Yuviwel® (navepegritide) New Drug Evaluation

2. Class Update/Prior Authorization Criteria

3. Public Comment

4. Discussion and Clinical Recommendations to OHA

3:40 PM

VI. EXECUTIVE SESSION

4:50 PM

VII. RECONVENE for PUBLIC RECOMMENDATIONS

VIII. ADJOURN